Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study
Year: 2004
Type: article
DOI: 10.1093/jac/dkh179
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2125911399
